Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's PACIFIC Update Bolsters Imfinzi's Lead In Stage III Lung Cancer

Executive Summary

Full PACIFIC data show strong overall survival benefit in all comers, though not in a post hoc analysis of those with low PD-L1 expression, about 20% of the population.

Advertisement

Related Content

Tagrisso Climbs Close To Top Of AstraZeneca Sales Tree
AZ Goes Into The MYSTIC And Finds Positives For Imfinzi
Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval
Mystic Miss Not Make Or Break For Imfinzi
Can Takeda's Alunbrig Take On Roche's Alecensa In First-Line ALK-Positive Lung Cancer?
AstraZeneca Looks To Deliver On Its Promises In Oncology
PACIFIC Pays Off Again For AZ With Imfinzi Lung Cancer OS Success
ARCTIC Chill Descends On AstraZeneca's Imfinzi/Treme Combo In NSCLC
AZ Rides PACIFIC Wave To Be First In Early-Stage NSCLC
AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel